DPP-1 inhibitors and macrolides likely reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, a network meta-analysis shows.
The buzzy term gets blamed for many diseases. But it isn’t all bad. Credit...Pete Gamlen Supported by By Nina Agrawal Illustrations by Pete Gamlen Inflammation has become a bit of a dirty word. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results